Net loss per share (GAAP) was $0.62, but remained negative as the company continues to invest heavily in research and development. The pivotal Phase 2 trial for Danon disease was placed on clinical ...

Lilly’s orforglipron cut body weight as expected in the Phase III ATTAIN-1 trial, but to a lesser extent than rival Novo ...

XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical ...

Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2025 and provided general business updates.

FDA approval of IBTROZI (taletrectinib) transformed Nuvation Bio into a commercial-stage company, driving $4.8 million in GAAP revenue, well above GAAP revenue estimates. Earnings per share (GAAP) was ...

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the second quarter ended ...

It feels like this shouldn't be happening,' says whistleblower of the clandestine dog testing at St. Joseph's Hospital in ...

As CEO of the psychedelic medicine company Compass Pathways, Kabir Nath has had a front-row seat to a dramatic year in the ...

Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today provided an update on recent and anticipated ...

Discover how AVA brings scale and reproducibility to organ‑chip technology, enabling human‑relevant insights that accelerate ...

Adjusted EBITDA (Q4): Adjusted EBITDA loss of $316,000 for Q4 FY2025, substantially narrowed from a $1.7 million adjusted ...